Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 5, 2026 | $7.27 | +13.4% | $783.30M | −1.9% | $6.86 |
| Q1 FY26ended Mar 31, 2026 | May 6, 2026 | $5.82 | −12.2% | $781.50M | −1.6% | $7.00 |
| Q4 FY25ended Dec 31, 2025 | — | $7.69 | +23.4% | $790.20M | +7.4% | — |
| Q3 FY25ended Sep 30, 2025 | — | $7.16 | +12.1% | $799.50M | +6.8% | — |
| Q2 FY25ended Jun 30, 2025 | — | $6.41 | +9.6% | $798.60M | +11.7% | — |
| Q1 FY25ended Mar 31, 2025 | — | $6.63 | +7.5% | $794.40M | +17.2% | — |
| Q4 FY24ended Dec 31, 2024 | — | $6.23 | +43.5% | $735.90M | +19.7% | — |
| Q3 FY24ended Sep 30, 2024 | — | $6.39 | +18.8% | $748.90M |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe United Therapeutics shares, not any token. As of Aug 5, 2026, from Massive's standardised financials and the earnings calendar.
| +22.9% |
| — |
| Q2 FY24ended Jun 30, 2024 | — | $5.85 | — | $714.90M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $6.17 | — | $677.70M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $4.34 | — | $614.70M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $5.38 | — | $609.40M | — | — |